REV1-POL ζ Inhibition and Cancer Therapy

In a recent issue of Cell, Wojtaszek et al. (2019) reported a small-molecule inhibitor of mutagenic translesion DNA synthesis, which targets the interaction between REV1 and REV7, sensitizes cancer cells to cisplatin in vitro and in vivo, and reduces mutagenesis. In a recent issue of Cell, Wojtaszek...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cell 2019-08, Vol.75 (3), p.419-420
Main Author: Taniguchi, Toshiyasu
Format: Article
Language:English
Subjects:
DNA Damage
DNA Repair
DNA Replication
DNA-Directed DNA Polymerase
Mutagenesis
Mutagens
Nucleotidyltransferases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a recent issue of Cell, Wojtaszek et al. (2019) reported a small-molecule inhibitor of mutagenic translesion DNA synthesis, which targets the interaction between REV1 and REV7, sensitizes cancer cells to cisplatin in vitro and in vivo, and reduces mutagenesis. In a recent issue of Cell, Wojtaszek et al. (2019) reported a small-molecule inhibitor of mutagenic translesion DNA synthesis, which targets the interaction between REV1 and REV7, sensitizes cancer cells to cisplatin in vitro and in vivo, and reduces mutagenesis.
ISSN:1097-2765
1097-4164
DOI:10.1016/j.molcel.2019.07.012